A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

• Main Authors: Antonios O. Aliprantis (Author), Christine A. Shaw (Author), Paul Griffin (Author), Nicholas Farinola (Author), Radha A. Railkar (Author), Xin Cao (Author), Wen Liu (Author), Jeffrey R. Sachs (Author), Christine J. Swenson (Author), Heather Lee (Author), Kara S. Cox (Author), Daniel S. Spellman (Author), Colleen J. Winstead (Author), Igor Smolenov (Author), Eseng Lai (Author), Tal Zaks (Author), Amy S. Espeseth (Author), Lori Panther (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older adults. A safe and effective RSV vaccine for older adults represents a serious unmet medical need due to higher morbid...